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Abstract: Long-term storage of biological samples from patients has become increasingly 
important in studies of disease control and treatment. The first nationwide Danish diabetes 
project, ie, The Danish Center for Strategic Research in Type II Diabetes (DD2), aims to improve 
treatment and the long-term outcome of patients with newly diagnosed type 2 diabetes (T2D). 
The DD2 project includes establishment of a biobank with samples from 50,000 patients with 
newly diagnosed T2D. This paper describes how blood and urine samples from 10,000 patients 
per year are collected, handled, and stored. The biobank includes whole blood, DNA, and 
plasma and urine samples, all frozen at -80°C. Sampling tubes have been standardized and are 
sent to hospital outpatient clinics and general practitioners where samples are taken, handled, 
aliquoted, and returned by mail overnight in standardized cryostorage tubes. When received at 
the biobank, samples are frozen without further treatment. From each patient, 24 cryostorage 
tubes are stored. Each tube is labeled with a barcode that links the data to other information 
available in a clinical databank registry. When patients are enrolled in DD2, a questionnaire is 
filled out and a quality monitoring system ensures that patients, samples, and questionnaires can 
be linked together at all times. The biobank is located at Vejle Hospital and the Danish National 
Biobank at Statens Serum Institut. As of the end of March 2012, samples from 1186 patients 
have been stored, and currently samples from 8–10 patients arrive per day. We have established 
the first national biobank in Denmark where blood, DNA, and plasma and urine samples from 
patients with newly diagnosed T2D are systematically collected and stored. This biobank enables 
sophisticated analysis of genetic variation and response to treatment, as well as disease marker 
studies that better classify disease status, progression, and complications.
Keywords: DD2, biobank, type 2 diabetes, logistics, implementation, biorepository, data 
registration
Introduction
The general purpose of a biobank is to collect biological samples for research that can 
be used to determine, for example, environmental exposure, physiologic functions, 
and the genetic composition and functioning of an individual.1 Furthermore, biobanks 
have become increasingly important in research studying new biomarkers for the 
prediction, diagnosis, progression, and treatment of disease.
The Danish Center for Strategic Research in Type 2 Diabetes (DD2) aims to opti-
mize treatment of patients with type 2 diabetes (T2D) by individualizing treatment. As 
part of the program, biological material and clinical information on 50,000 incident 
patients with T2D will be collected over a 5-year period. Detailed information will be 
gathered on all those enrolled with respect to social characteristics, disease phenotype, 
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genetics, and other biomarker characteristics. To achieve this 
and to study the long-term impact on outcome, there is a need 
to gain knowledge about patients at registration when clinical 
data are collected, as described by Nielsen et al,2 and to obtain 
biological samples to be stored in a biobank, as described 
in this paper. To follow clinical outcomes for this cohort 
of patients with newly diagnosed T2D, the registered data 
will subsequently be linked to different Danish population-
based registries. This will provide unique outcome data, as 
described by Thomsen et al3 and Beck-Nielsen et al.4 In brief, 
the aims of this paper are to describe the biobank logistics and 
how the biological samples are collected, handled, shipped, 
and stored.
Biobank organization and logistics
Organization
According to the Danish law on biomedical research ethics, 
it is required that patients give their signed informed consent 
prior to participation in a research project and storage of per-
sonal biological samples.5 A DD2 application is sent to and 
approved by the Danish National Committee on Biomedical 
Research Ethics (record number S-20100082) and the Danish 
Data Protection Agency (record number 2008-58-0035) prior 
to collection, storage, and entry of any personalized data in 
the biobank and database. The diagnosis of T2D is given 
according to the World Health Organization6 and recom-
mendations by the Danish National Board of Health.7
The biobank is administered by the DD2 partners listed 
on the http://www.dd2.nu website. Each patient may, at any 
time, request withdrawal from the project and, consequently, 
samples and data from this patient will be destroyed and the 
patient registered as having dropped out. Furthermore, DD2 is 
an open project where researchers are able to present project 
proposals and gain access to collected biological material and 
clinical data. The patients participating in the project are not 
given compensation or other benefits for donating blood and 
urine. The biobank will be located at the Laboratory Centre at 
Vejle Hospital (ISO 15189 accredited) and at the newly estab-
lished Danish National Biobank at Statens Serum Institut. 
The institutions will be responsible for the compliance of the 
biobank with Danish law.
Logistics
The prospective DD2 project aims to improve T2D treatment, 
as described in detail by Steffensen et al.8 This will be done 
by gathering clinical and biological material nationwide from 
newly diagnosed T2D patients. This will only be possible 
if the logistics for sampling and handling are simple and 
can be performed at hospital outpatient clinics, by general 
practitioners, and at other places in the health care system 
where patients with T2D are encountered. This requirement is 
balanced by the need to retrieve samples of high quality under 
perfect standardized conditions. Care was therefore taken 
to develop a collection strategy where the highest possible 
sample quality is achieved, allowing nationwide sampling 
of different sample types. To standardize the procedure as 
much as possible, all materials for sampling and shipping 
are assembled in a DD2 sampling kit, and one is prepared 
for each patient to be enrolled.
A detailed description of sampling and handling was 
initially written and made available on the DD2 website. 
Later this was accompanied by video instructions for pre-
paring the buffy coat. Following sampling and handling, 
the collected biological material is packed in certified 
packaging, contained in the kits, and mailed overnight to 
the biobank (see Figure 1). Most biochemical markers are 
stable for up to 30 hours.9–11 At the biobank, samples are 
received and immediately stored at -80 °C in freestanding 
 freezers.  Currently, the laboratory centre at Vejle Hospital has 
employed a specialist in bioinformatics who is responsible 
for the biobank database administration and a biotechnologist 
who is responsible for all logistics. Similar activities have 
been established at the Danish National Biobank, including 
the establishment of a Danish National Biobank Registry 
(http://www.nationalbiobank.dk).
Figure 1 Complete sampling kit for The Danish Center for Strategic Research in 
Type II Diabetes.
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The above description of the DD2 biobank illustrates that 
the setup includes an entity that receives, stores, processes, 
and/or disseminates specimens, as needed, encompasses 
the physical location as well as the full range of operational 
activities, is one freezer or a separate unit or part of an 
institution, and has professional staff and a commitment to 
maintaining and preserving specimens and records for future 
and historical continuity. The DD2 biobank thus fulfils the 
definition and criteria for a biorepository.1,12
Procedures for sampling  
and storage
Sampling kit
A DD2 sampling kit is prepared for each patient to be 
enrolled. Kits are packed in boxes containing 5, 10, 25, or 50 
kits labeled with shelf-life expiration data and sent to the local 
sampling sites. Each sampling kit contains 12 primary blood 
sampling tubes and one tube for urine sampling. Further, it 
contains 22 secondary cryostorage tubes, 25 labels with bar-
codes, and material for packing and sending samples safely 
to the biobank according to Danish law (see Figure 1). The 
12 primary blood sampling tubes allow a wide spectrum of 
different analyses to be conducted and consist of tubes with 
lithium heparin, sodium citrate, potassium ethylenediamine 
tetra-acetic acid (EDTA), sodium fluoride citrate, and clot 
activator (Table 1).
Local procedures
Each patient’s signed informed consent to donate blood and 
urine to the DD2 project is checked before sampling. Prior to 
the sampling day, patients are informed by the local DD2 per-
sonnel to arrive in the morning after 8 hours of fasting, prior 
to taking morning medication, and to bring a morning urine 
sample. If patients forget the urine sample, a spot sample is 
taken on site and this is registered. Further, in case the patient 
is not fasting, blood samples are taken, and this is registered 
and information is sent with the samples to the biobank or 
is marked on the online registration form (for details, see 
Nielsen et al2). Fasting blood samples have been obtained 
from 940 of the first 1186 patients enrolled in DD2.
Blood sample tubes are always filled in the order outlined 
in Table 1 and each tube is carefully mixed by turning the 
tube upside down 10 times. At least 30 minutes and no later 
than 2 hours after sampling, all samples except the urine and 
whole blood EDTA tubes are centrifuged for 10 minutes at 
1500–2000 g, and the desired content is then immediately 
transferred to a cap color-matching cryostorage tube using 
a pipette.
The 25 labels provided in the sampling kit have an eight-
digit printed barcode, where the first six digits are consecutive 
unique numbers and the last two are a series from 01 to 24, 
and they are placed on the cryostorage tubes to identify the 
content of each of the tubes. The last label has “00” as the 
last two digits and is used to identify and link the patient 
with their civil registration number on the request form that 
is sent to the biobank together with the samples. In this way, 
samples are linked to an individual personal civil registration 
number. The civil registration number is used nationwide to 
store individual personal data in Danish population-based 
databases, and can therefore be used when DD2 data are 
subsequently linked to the different Danish population-based 
databases, as described by Thomsen et al.3
Procedures at biobank and storage
Upon receiving the samples at the biobank they are visu-
ally inspected for volume and appearance in the form of 
hemolysis, possible coagulation, and buffy coat quality. 
Each sample is identified and registered in a database. The 
data shown in Table 2 are registered in this database, and 
each sample is assigned to a predetermined position in the 
Table 1 List of primary sampling tubes contained in the sampling kit for The Danish Center for Strategic Research in Type II Diabetes 
(further details on local processing are given in the fourth column)
Number of tubes Tube volume Additive Processing
2 9 mL Lithium heparin Spun and plasma is aliquoted into four cryostorage tubes
2 2.7 mL Citrate Spun and plasma is aliquoted into two cryostorage tubes
2 9 mL EDTA Spun, the plasma is aliquoted into four cryostorage tubes, and the 
buffy coat is skimmed and aliquoted in two cryostorage tubes
2 4 mL EDTA No processing, whole blood sent in primary tubes
2 3 mL Fluoride citrate Spun and plasma is aliquoted into two cryostorage tubes
2 9 ml None Spun and plasma is aliquoted into four cryostorage tubes
1 10 mL Conical tube for urine Urine aliquoted into four cryostorage tubes
Total 13 Total mL blood = 73.4  Total aliquots frozen = 24
Abbreviation: EDTA, ethylenediamine tetra-acetic acid.
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freezers identified in a three-dimensional system for easy later 
retrieval. Key information linking the barcode on the tubes 
in the Biobank to the patient identification is only present in 
the database. Thus, samples in the Biobank cannot be linked 
to an individual person without access to the database. The 
database is stored on an offline computer and protected by 
an access code known by two persons. A back-up of the 
database is performed daily. A copy of the content is also 
stored in a secure safe.
The freezers used operate at –80°C. The temperature is 
centrally logged for alarm purposes to ensure an emergency 
electrical supply. Of all samples sent to the biobank, 94% 
were frozen within 30 hours after sampling. The delayed 
samples (6%) are not discarded, but the delay is registered in 
the database. In 2.8% of the samples, the buffy coat contain-
ing the DNA material was not isolated correctly; however, 
DNA from all these samples has been secured by storing 
whole blood samples.
Quality and sample limitations
Based on experience from the diabetes biobank at Vejle 
where patient samples were handled and stored at 5°C, 
it was initially proposed to handle and transport samples 
at 5°C, but most general practitioners do not have the 
equipment for handling blood samples at low tempera-
ture. Establishing a nationwide transport system for blood 
samples at 5°C would also be expensive. Thus, to increase 
the number of sampling sites and reduce costs, all samples 
are taken and processed at room temperature and sent by 
ordinary mail.
Storing different types of plasma enables later analysis 
of a wide range of biomarkers and substances in the blood 
of patients with newly diagnosed T2D. In brief, lithium 
heparin tubes are used to obtain plasma for biochemistry 
analysis. Potassium EDTA is the standard anticoagulant 
used for hematology and biochemistry because it preserves 
the cellular components of blood. However, potassium, 
sodium, and some enzymes may not be measured due to 
addition of potassium to the sample, and because calcium 
and magnesium is chelated by EDTA. Sodium fluoride citrate 
is used for accurate glucose (and lactate) determination due 
to inhibition of the enzyme systems involved in glycolysis. 
Finally, DNA extraction and genetic analysis are possible 
from the separated buffy coat collected from potassium 
EDTA tubes or from the whole blood sample stored in EDTA 
tubes. Research groups can apply to the board of the DD2 
partners (http://www.dd2.nu) for specimens and patient data 
in specific research projects.
Biobank status
The Biobank is projected to receive 50,000 patients and to 
store at least 1.2 million individual samples. As of March 
2012, 1186 blood and urine samples have been received from 
65 sampling sites located nationwide. At present, sample 
collection is increasing substantially (Figure 2) and the enrol-
ment rate has increased by a factor of 5.8 since spring 2011 
when the first sites started officially after a short test phase. 
The 1186 enrolled patients have yielded a total of 25,968 
cryostorage tubes and 2268 primary sample tubes stored in 
the DD2 bank at present.
Perspectives
In 2009, Time magazine published a special issue on ten 
ideas that are changing the world, where the formation of 
biorepositories for research and better diagnosis and treat-
ment of disease was one of the ten.13
The DD2 database and Biobank will enable researchers 
to add to the knowledge about T2D and further increase the 
quality of medical care, both in general and for individual 
patients. For example, in the future, markers may be found 
to be predictive for the effect of a certain drug. All patients 
could be investigated for this trait immediately and have 
their treatment changed, giving the same standard of care 
irrespective of residence in the country.
Furthermore, new analytical tests for newly discovered 
biochemical or genetic components of possible importance 
in T2D can be tested retrospectively before being used pro-
spectively. However, one should be aware that the nationwide 
multicenter approach using a practical way of collecting 
samples and mailing them overnight may jeopardize analy-
ses and data acquisition for unstable or fragile metabolic or 
biochemical components.
Table 2 Individual information registered in the biobank database 
for each individual sample
Database fields
Project identification (barcodes 00–24)
Civil registration number
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Conclusion
To the best of our knowledge, biological samples and clini-
cal data from a large cohort of newly diagnosed patients 
with T2D have not previously been stored together in a 
biobank and database on a nationwide scale. A nationwide 
biobank program has been developed to store blood, DNA, 
and plasma and urine samples from patients with newly 
diagnosed T2D. A total of 1,200,000 samples from 50,000 
patients will be collected and stored over a 5-year period. As 
of March 2012, samples from 1186 newly diagnosed T2D 
patients have been received. The DD2 biobank together 
with the DD2 database that is linked to the different Danish 
population-based registries provides a unique infrastructure 
for studying the progression of T2D. It is our hope that 
this new facility will lead to new knowledge about how 
patient stratification can be optimized and tailored treatment 
implemented in the health care system, both nationally and 
internationally.
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